BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22214756)

  • 1. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.
    Prayle AP; Hurley MN; Smyth AR
    BMJ; 2012 Jan; 344():d7373. PubMed ID: 22214756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compliance on Mandatory Data Reporting in Registered Obstetrics Trials.
    Checketts JX; Evans MB; Athale AH; Jawhar OM; Wright MR; Bryant K; Vassar M
    Am J Perinatol; 2018 Oct; 35(12):1192-1196. PubMed ID: 29695018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with results reporting at ClinicalTrials.gov.
    Anderson ML; Chiswell K; Peterson ED; Tasneem A; Topping J; Califf RM
    N Engl J Med; 2015 Mar; 372(11):1031-9. PubMed ID: 25760355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.
    DeVito NJ; Bacon S; Goldacre B
    Lancet; 2020 Feb; 395(10221):361-369. PubMed ID: 31958402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov.
    Law MR; Kawasumi Y; Morgan SG
    Health Aff (Millwood); 2011 Dec; 30(12):2338-45. PubMed ID: 22147862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
    Miller JE; Korn D; Ross JS
    BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
    Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
    Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
    Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
    BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov.
    Riley IL; Boulware LE; Sun JL; Chiswell K; Que LG; Kraft M; Todd JL; Palmer SM; Anderson ML
    Clin Trials; 2018 Feb; 15(1):87-94. PubMed ID: 29121787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research without results: inadequate public reporting of clinical trial results.
    Gopal RK; Yamashita TE; Prochazka AV
    Contemp Clin Trials; 2012 May; 33(3):486-91. PubMed ID: 22342449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial reporting performance of thirty UK universities on ClinicalTrials.gov-evaluation of a new tracking tool for the US clinical trial registry.
    Keestra SM; Rodgers F; Lenz D; Osborne R; Bruckner T; Lee S
    Trials; 2021 Jun; 22(1):375. PubMed ID: 34074329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis.
    Ross JS; Mulvey GK; Hines EM; Nissen SE; Krumholz HM
    PLoS Med; 2009 Sep; 6(9):e1000144. PubMed ID: 19901971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
    Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
    BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial Reporting in ClinicalTrials.gov - The Final Rule.
    Zarin DA; Tse T; Williams RJ; Carr S
    N Engl J Med; 2016 Nov; 375(20):1998-2004. PubMed ID: 27635471
    [No Abstract]   [Full Text] [Related]  

  • 16. Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors.
    Hirsch L
    Curr Med Res Opin; 2008 Jun; 24(6):1683-9. PubMed ID: 18462565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA.
    Talebi R; Redberg RF; Ross JS
    Trials; 2020 Jul; 21(1):675. PubMed ID: 32703252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
    Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
    BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The obstetrical research landscape: a cross-sectional analysis of clinical trials from 2007-2020.
    Steinberg JR; Weeks BT; Reyes GA; Conway Fitzgerald A; Zhang WY; Lindsay SE; Anderson JN; Chan K; Richardson MT; Magnani CJ; Igbinosa I; Girsen A; El-Sayed YY; Turner BE; Lyell DJ
    Am J Obstet Gynecol MFM; 2021 Jan; 3(1):100253. PubMed ID: 33043288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis.
    Ross JS; Tse T; Zarin DA; Xu H; Zhou L; Krumholz HM
    BMJ; 2012 Jan; 344():d7292. PubMed ID: 22214755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.